TAmiRNA presenting biomarker advantages at BIO International


TAmiRNA presenting biomarker advantages at BIO International


tamirna_logo

Press Release | TAmiRNA GmbH

JUNE 05, 2017

Vienna, Austria: – Innovative biotech company TAmiRNA will join scores of potential partners at the big BIO International Convention in San Diego next month to present powerful diagnostic advantages for its unique OsteomiR™ and ThrombomiR™ biomarker technologies.

TAmiRNA will exhibit at Booth 5323 in the Advantage Austria Pavilion at the San Diego Convention Center.

“We have been attending this event since 2014 because it works well for us. Based on partnering meetings we have been able to build a number of important partnerships,” said TAmiRNA CEO Dr. Matthias Hackl, who will be attending the convention, along with CFO Otto Kanzler.

At BIO International 2017, TAmiRNA will be seeking to recruit partners for the co-development of in-vitro diagnostic tests using its circulating microRNAs, as well as distributors and marketers for its research-use only tests.

Molecular diagnostic advantage

“We have arranged meetings with biotech and pharma companies with active drug development programs in musculoskeletal and cardiovascular disease, along with MedTech companies active in molecular diagnostics,” commented Otto Kanzler.

“We believe they will be particularly interested in our unique technologies, such as the osteomiR™ signature biomarker that predicts the risk for osteoporotic fractures in post-menopausal and type-2 diabetic women and the thrombomiR™ signature biomarker that provides a validated surrogate of platelet activation that can be used to measure the change in platelet function and reactivity in response to pharmacological treatments,” said Mr. Kanzler.

OsteomiR™ and ThrombomiR™ biomarkers

The osteomiR™ test performs independently of bone mineral density and can be used in combination with established risk scores, such as FRAX, by pharmaceutical companies to select high-fracture-risk subsets for clinical studies, and by doctors for treatment decision support.

TAmiRNA’s thrombomiRs™ test is the first standardized test kit for analysis of platelet-derived circulating microRNAs and can be used to identify non-responders, adjust drug doses and reduce bleeding risk. Its main advantages over other available platelet function tests are that it is independent of activators such as ADP and collagen and also enables retrospective analysis of frozen plasma.

CRO Services

TAmiRNA will also be seeking customers for its recently added CRO Services that offer solutions to companies that require complementary and companion biomarker solutions for their drug development programs. The service portfolio includes Analytical Services providing nucleic acid analysis in any type of liquid or solid-tissue biopsy, as well as Biomarker Development Services, a one-stop service for the development of biomarkers.

Since TAmiRNA last appeared at BIO International it has reached agreement with the international company Biomedica for global distribution of TAmiRNAs OsteomiR™ test kit as well as forging a partnership with Swiss-based in silico biomarker and bioinformatics specialist SimplicityBio to create compelling new biomarker development services to clients from academia and biotech industry.

About TAmiRNA

Privately owned and headquartered in Vienna, TAmiRNA GmbH is a biotech company specialized in the identification and validation of non-coding RNAs as biomarkers for age-related diseases. The mission of TAmiRNA is to provide clinically useful biomarkers to improve and prolong patient stability, health and quality of life with increasing age.

TAmiRNA specializes in technologies for profiling levels of blood-circulating microRNAs and developing multi-parametric classification algorithms (“signatures”). TAmiRNA uses these technologies to develop minimal-invasive diagnostic tests for early diagnosis and prognosis of age related disease, or as companion diagnostic tests to support treatment decisions.

TAmiRNA’s pipeline includes developments in osteoporosis, cardiovascular disease, type-2 diabetes, and cancer developing ‘microRNA kit’ solutions that enable users to quantify the levels of specific microRNA combinations in serum, plasma, urine or other biofluids. The company initially developed kits for bone quality (osteomiR™) and platelet function (thrombomiRs™).

TAmiRNA also offers contract research services for companies in need of targeted biomarker development. Customers include biopharma companies with drug development programs in human and veterinary medicine, medtech companies and clinical research groups.

More information available at: www.tamirna.com

About BIO International

The BIO International Convention (BIO) provides a week of intensive networking for biotechnology and pharma leaders to discover new opportunities and promising partnerships. It attracts more than 16,000 delegates involved in a wide spectrum of life science and application areas including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy.

BIO International 2017 is a four -day event opening June 19 at the harbor-side San Diego Convention Center in southern California. The convention will feature more than 35,000 face-to-face meetings for some 3,100 companies organised using the proprietary BIO One-on-One partnering™ system, as well as hundreds of individual company presentations, a program of world-renowned keynote speakers and some 20 Session Tracks.

The event is organized by the Washington DC-based Biotechnology Innovation Organization, the world’s largest trade association of academic institutions, state biotechnology centers and related organizations.

More information at: http://convention.bio.org

Media Contact

Dr. Elisabeth Schraml, Scientific Communications, TAmiRNA GmbH
Tel: +43 (0)660 420 58 56
Email: office@tamirna.com

Resources

Click on TAmiRNA at BIO International for other information.
Click on TAmiRNA to contact the company directly.

Dr. Matthias Hackl, CEO, TAmiRNA GmbH

Dr. Matthias Hackl, CEO, TAmiRNA GmbH

TAmiRNA uses microRNA biomarkers to develop diagnostics and monitor disease progression, including transcription in the cell nucleus (1), microRNA processing in the cell cytoplasm (2), RNA interference or gene silencing (3),  microRNAs packaged by donor cell into microvesicles/exosomes for cellular export (4/5),  microRNAs stabilized by RNA-binding proteins (6),  microRNAs detected in various biofluids including serum/plasma, urine or saliva (7) and circulating microRNAs taken up by acceptor cells at close or distant sites in the body (8).

TAmiRNA uses microRNA biomarkers to develop diagnostics and monitor disease progression, including transcription in the cell nucleus (1), microRNA processing in the cell cytoplasm (2), RNA interference or gene silencing (3), microRNAs packaged by donor cell into microvesicles/exosomes for cellular export (4/5), microRNAs stabilized by RNA-binding proteins (6), microRNAs detected in various biofluids including serum/plasma, urine or saliva (7) and circulating microRNAs taken up by acceptor cells at close or distant sites in the body (8)


Supplier Information
Supplier: TAmiRNA GmbH
Address: Muthgasse 18, 1190 Vienna, Austria
Tel: +43 (0)660 420 58 56
Website: www.tamirna.com


Comments are closed.